Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the ...

Pfizer announced it is ending its development of a once-daily weight-loss pill treatment for obesity. It comes after a participant in one of the trials experienced a possible drug-induced liver injury ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike GLP-1 drugs, which are administered via injection and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...